Affimed (Group)

https://www.affimed.com

Affimed Therapeutics AG is a therapeutic antibody company developing unique antibody therapeutics as novel treatments for life threatening diseases with high unmet medical needs. The company has generated a growing pipeline of drug candidates based on its proprietary TandAb® antibody platform. Affimed's product candidates are developed for the treatment of CD19-positive (AFM11) and CD30-positive tumors (AFM13). Further novel product candidates are in development to treat solid tumors and autoimmune diseases. Affimed's proprietary and highly productive TandAb® technology enables the company to generate unique tetravalent, bispecific, fully human antibody formats that promise increased therapeutic potential and superior profiles compared to monoclonal antibodies. The private company Affimed, which employs 30 people in Heidelberg, is a spin-off from the German Cancer Research Centre (DKFZ), Heidelberg. About TandAbs®: TandAbs®, which were invented and developed by Affimed scientists, are tetravalent bispecific antibody formats that have two binding sites for each antigen. RECRUIT-TandAbs®, such as AFM11 and AFM13, bind to target molecules on the surface of tumor cells (CD19 and CD30, respectively) and can activate immune effector cells such as cytotoxic T-cells or natural killer (NK) cells. RECRUIT-TandAbs® possess the same avidity and affinity for each target as an IgG; however, the much higher potency of TandAbs® versus IgG is achieved by a more efficient binding to the immune effector cells. Combined with their bispecificity, this format represents a potent further development of therapeutic monoclonal antibodies and, potentially, a superior alternative to first generation antibody formats/scaffolds. A robust production process for TandAbs has been established with excellent stability of the drug product. Affimed has developed different kinds of TandAbs® for specific indications. While RECRUIT-TandAbs® are applied to oncology, BiBLOCK- and PROLONG-TandAbs® are developed for the treatment of autoimmune and inflammatory diseases. *

	Start	2000-05-01 splitoff
	Predecessor	DKFZ (German Cancer Research Center, GCRC)
	Industry	MAb, human, fully
	Industry 2	TandAb bispecific antibody
	Person	Hoess, Adi (Affimed 201109– CEO before CCO before Jenowis + Jerini 2003– + Carl Zeiss AG + MorphoSys AG)
	Person 2	Fischer, Florian (MedVenture Partners 201305 Managing Director + Affimed CFO 201510)

	Region	Heidelberg
	Country	Germany
	Street	582 Im Neuenheimer Feld Technologiepark Heidelberg
	City	69120 Heidelberg
	Tel	+49-6221-65307-0
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2021-12-31)
	Currency	EUR
	Annual sales	40,366,000 (revenue, consolidated (2021) 2021-12-31)
	Profit	-57,523,000 (2021-12-31)
	Cash	197,630,000 (2021-12-31)

		* Document for »About Section«:

		Record changed: 2023-07-10